Carisma Therapeutics, Inc.
CARM
$0.06
$0.019.62%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 159.68% | -48.01% | 32.45% | 31.59% | 41.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 159.68% | -48.01% | 32.45% | 31.59% | 41.13% |
| Cost of Revenue | -56.93% | -46.35% | -31.46% | -19.50% | -12.75% |
| Gross Profit | 158.45% | 45.68% | 47.55% | 32.37% | 25.99% |
| SG&A Expenses | -47.18% | -34.29% | -26.76% | -31.79% | 1.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.29% | -43.24% | -30.27% | -23.00% | -9.30% |
| Operating Income | 119.24% | 41.94% | 41.36% | 32.18% | 18.17% |
| Income Before Tax | 112.57% | 32.08% | 37.58% | 30.39% | 22.39% |
| Income Tax Expenses | -- | -- | -- | -- | -200.00% |
| Earnings from Continuing Operations | 112.61% | 31.89% | 37.49% | 30.39% | 22.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 112.61% | 31.89% | 37.49% | 30.39% | 22.82% |
| EBIT | 119.24% | 41.94% | 41.36% | 32.18% | 18.17% |
| EBITDA | 122.37% | 42.10% | 41.46% | 33.84% | 19.57% |
| EPS Basic | 112.33% | 33.60% | 39.31% | 57.94% | 85.26% |
| Normalized Basic EPS | 121.73% | 42.44% | 41.78% | 59.25% | 85.20% |
| EPS Diluted | 112.08% | 33.60% | 39.31% | 57.94% | 85.26% |
| Normalized Diluted EPS | 121.48% | 42.44% | 41.78% | 59.25% | 85.20% |
| Average Basic Shares Outstanding | 1.60% | 2.29% | 2.95% | 24.01% | 72.16% |
| Average Diluted Shares Outstanding | 1.70% | 2.29% | 2.95% | 24.01% | 72.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |